Glasoxmithkline plc, of London, said data published in Respiratory Medicine showed positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta (umeclidinium /vilanterol), the combination long-acting muscarinic antagonist (LAMA)/long-acting beta2-adrenergic agonist, with the LAMA tiotropium, administered in the Handihaler inhaler, in patients with chronic obstructive pulmonary disease.